CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced a significant milestone in its partnership with Quazar Investment. Following the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates (UAE), the closing of the previously announced $50 million strategic partn ...

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. The FDA’s decision follows the successful completion of the Phase I dose-escalation study, which demonstra ...

Quazar Chairman and Executive Team with NeOnc's Executive's and Directors at Quazar's Headquarters in Dubai. CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed ...

CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled "AI and Biotech Take on Brain Cancer." This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sectio ...

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Josh Neman as Chief Clinical Officer to enhance its clinical development strategy and accelerate clinical trials, particularly for its lead asset NEO100, which is nearing completion of Phase 2a ahead of schedule [1][5]. Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on innovative therapies for central nervous system cancers, with lead programs including NEO100 and NEO212 designed to bypass the blood-brain barrier [6]. Leadership Appointment - Dr. Neman joins from the Keck School of Medicine at USC, where he has significant experience in cancer neuroscience and has led various cancer research initiatives [2][3]. - His expertise in brain tumor biology and clinical leadership is expected to be instrumental in advancing NeOnc's mission to improve treatment outcomes for patients with life-threatening cancers [5]. Clinical Trials and Development - NeOnc is currently conducting four clinical trials, with NEO100's Phase 2a trial achieving full enrollment ahead of schedule [5]. - The company aims to integrate AI and quantum computing into its drug delivery platform, enhancing its precision therapies [5]. Research and Innovation - NeOnc's proprietary formulations and extensive patent portfolio (176 patents worldwide) reflect its strong potential for commercialization in the CNS cancer treatment market [6].